EUVIMEDObjevte EUVIMED
Übersichtsarbeit

The role of anticomplement therapy in the management of the kidney allograft

Mehmet Kanbay iD, Sidar Copur, Zeynep Y Yilmaz, Dilek Ertoy Baydar, Ilmay Bilge, Caner Susal, Burak Kocak, Alberto Ortiz

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15277 ↗

At a glance

Übersichtsarbeit in Clinical Transplantation, 2024. Written by Mehmet Kanbay and 7 co-authors. Institution: Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. Major MEDLINE topics: Kidney, Kidney Transplantation, Complement Inactivator Proteins. Cited 9 times so far (Crossref); 82 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

As the number of patients living with kidney failure grows, the need also grows for kidney transplantation, the gold standard kidney replacement therapy that provides a survival advantage. This may result in an increased rate of transplantation from HLA‐mismatched donors that increases the rate of antibody‐mediated rejection (AMR), which already is the leading cause of allograft failure. Plasmapheresis, intravenous immunoglobulin therapy, anti‐CD20 therapies (i.e., rituximab), bortezomib and splenectomy have been used over the years to treat AMR as well as to prevent AMR in high‐risk sensitized kidney transplant recipients. Eculizumab and ravulizumab are monoclonal antibodies targeting the C5 protein of the complement pathway and part of the expanding field of anticomplement therapies, which is not limited to kidney transplant recipients, and also includes complement‐mediated microangiopathic hemolytic anemia, paroxysmal nocturnal hemoglobinuria, and ANCA‐vasculitis. In this narrative review, we summarize the current knowledge concerning the pathophysiological background and use of anti‐C5 strategies (eculizumab and ravulizumab) and C1‐esterase inhibitor in AMR, either to prevent AMR in high‐risk desensitized patients or to treat AMR as first‐line or rescue therapy and also to treat de novo thrombotic microangiopathy in kidney transplant recipients.

Subjects

MeSH terms (MEDLINE)

KidneyKidney TransplantationComplement Inactivator ProteinsHumansTransplantation, HomologousAllograftsGraft Rejection

Author keywords

allograft lossantibody-mediated rejectioncomplement system proteinsdesensitizationeculizumabthrombotic microangiopathy

Substances

anticomplementComplement Inactivator Proteins

Authors and institutions

  • Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
  • Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
  • Department of Pathology, Koc University School of Medicine, Istanbul, Turkey.
  • Department of Pediatrics, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
  • Transplant Immunology Research Center of Excellence, Koc University Hospital, Istanbul, Turkey.
  • Department of Urology, Koc University School of Medicine, Istanbul, Turkey.

ORCID profiles: Mehmet Kanbay

Cite

APA

Kanbay, M., Copur, S., Yilmaz, Z. Y., Baydar, D. E., Bilge, I., Susal, C., Kocak, B., & Ortiz, A. (2024). The role of anticomplement therapy in the management of the kidney allograft. Clinical Transplantation. https://doi.org/10.1111/ctr.15277

Vancouver

Kanbay M, Copur S, Yilmaz ZY, Baydar DE, Bilge I, Susal C, et al. The role of anticomplement therapy in the management of the kidney allograft. Clinical Transplantation. 2024. doi:10.1111/ctr.15277

BibTeX
@article{Kanbay2024,
  author = {Kanbay, Mehmet and Copur, Sidar and Yilmaz, Zeynep Y and Baydar, Dilek Ertoy and Bilge, Ilmay and Susal, Caner and Kocak, Burak and Ortiz, Alberto},
  title = {The role of anticomplement therapy in the management of the kidney allograft},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15277}
}
Start for free →